Jim Cramer's Enthusiasm for Elanco Animal Health
On a recent episode of CNBC's "Mad Money Lightning Round," Jim Cramer expressed his strong conviction in Elanco Animal Health Incorporated (NYSE: ELAN). Cramer stated, "They are doing everything right. I am so impressed with the way they've turned that company around," indicating a promising future for Elanco.
Analyst Support for Elanco
Adding weight to Cramer's endorsement, Barclays analyst Glen Santangelo has initiated coverage on Elanco Animal Health with an Overweight rating, setting a price target of $30. This positive outlook from analysts further solidifies Elanco's strong positioning within the animal health sector, suggesting investors might find value in the stock at its current price.
Insights on Other Stocks in the Spotlight
During the segment, Jim Cramer also discussed several other stocks. He pointed to Rocket Lab Corporation (NASDAQ: RKLB) as a solid speculative investment, highlighting the company’s trajectory ahead of a significant launch. Cramer noted, "Rocket Lab is a very good spec as we look toward future offerings in the rocket world. You can own it as your spec play."
Updates on Rocket Lab's Operations
In an exciting announcement, Rocket Lab revealed that its next Electron rocket launch would occur sooner than expected, featuring the STP-S30 mission for the U.S. Space Force's Space Systems Command. This accelerated timeline underscores Rocket Lab's growing importance in responsive space activities.
Cramer's Sell Recommendations
While Cramer championed Elanco and Rocket Lab, he advised caution regarding Lithium Americas Corp (NYSE: LAC), describing it as a "yesteryear stock" that he believes investors should avoid. This caution may stem from shifting market dynamics and expectations surrounding energy stocks in the wake of fluctuating lithium prices.
Performance of Other Stocks Analyzed
Cramer also touched on Daktronics, Inc. (NASDAQ: DAKT). He commented that while Daktronics is performing satisfactorily, it does not present a compelling case for investment, stating, "It's just ok. It's just not compelling enough to put your money into." Meanwhile, Daktronics recently reported second-quarter results that beat expectations, showcasing resilience amid tough market conditions.
Positive Changes for M&T Bank
Cramer showed optimism about M&T Bank Corporation (NYSE: MTB), labeling it a "very well-run bank". Analysts maintain favorable views with improved price targets, highlighting a strong operational framework and potential for growth within the banking sector.
Ondas Holdings: A Note of Caution
When discussing Ondas Holdings Inc (NASDAQ: ONDS), Cramer stated, "I'm going to have to take a pass," suggesting a more cautious approach amidst the latest developments for the company, which recently completed its acquisition of Roboteam Ltd.
Market Summary of Recent Stock Movements
In the broader market context, Elanco's shares dropped by 1.8%, settling at $22.08. Rocket Lab shares also declined by 2.8% to close at $53.96, while Lithium Americas fell by 3.6% to settle at $4.61. Daktronics shares slipped by 0.9% to $19.02, whereas M&T Bank shares rose by 1% to conclude at $206.12. Ondas Holdings saw a more significant dip of 6.1%, settling at $7.60.
Frequently Asked Questions
What did Jim Cramer say about Elanco Animal Health?
Cramer praised Elanco for successfully turning its business around, highlighting its strong operational decisions and future potential.
What stock did Barclays initiate coverage on?
Barclays initiated coverage on Elanco Animal Health with an Overweight rating and a price target of $30.
Which company did Cramer recommend as a speculative play?
Cramer recommended Rocket Lab Corporation as a speculative investment, pointing to its promising upcoming launches.
What is Cramer's opinion on Lithium Americas Corp?
Cramer advised against investing in Lithium Americas, referring to it as a "yesteryear" stock.
How did Daktronics perform recently?
Daktronics recently reported better-than-expected financial results, although Cramer remains noncommittal about recommending it as a compelling investment.
